You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of VPL Vaccine for RSV

    SBC: SIGMOVIR BIOSYSTEMS, INC.            Topic: NIAID

    Project Summary Human respiratory syncytial virus (RSV) is recognized as the single most important viral cause of acute respiratory disease in infants and young children worldwide. Elderly populations and immunocompromised individuals are also at significant risk for serious RSV disease. Despite this very substantial disease burden imposed by RSV worldwide, there are no vaccines available. Severa ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Orally available transition state inhibitors for triple negative breast cancer

    SBC: NANOMETICS LLC            Topic: NCI

    Problem to be Solved: Triple-negative breast cancer (TNBC) is a deadly disease that accounts for 15-20% of all diagnosed breast cancers worldwide. Metastatic relapse of TNBC carries a poorer prognosis and lower survival rate compared to other breast cancersubtypes. Therefore, identifying novel targets and new therapeutics to treat patients diagnosed with TNBC remains a significant priority of the ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Novel Focal Adhesion Kinase autophosphorylation inhibitors against pancreatic cancer

    SBC: CUREFAKTOR PHARMACEUTICALS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Due to the absence of effective therapies, pancreatic cancer is the fourth leading cause of cancer deaths in both men and women. This study focuses on the development of new small molecule inhibitors targeting Focal Adhesion Kinase against pancreatic cancer. Focal Adhesion Kinase (FAK) has been shown to play an important role in tumor cell survival, including p ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Modified RNA tools and diagnostics for drug abuse

    SBC: ATHGHIN BIOTECHNOLOGY, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): Project Summary/Abstract RNA modifications are numerous, and range from simple methylation to complex changes such as addition of aminoacylcarbamoyl moieties. These modifications and, the levels at which are present, are emerging as important regulators of biological processes, and perturbations such as chemical or drug exposure can alter the patterns of specif ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Removal of Amyloid-beta Peptides from the Alzheimer's Brain

    SBC: WE BIOSCIENCES, LLC            Topic: NIA

    DESCRIPTION (provided by applicant): As the Alzheimer's disease (AD) population is growing rapidly, currently there are no cure treatments. The goal of this resubmitted STTR proposal is to conduct a preclinical study with pramlintide to prove a potential treatment for AD. We have revised the proposal significantly according to the reviewers' comments. Pramlintide is an FDA approved drug ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Evaluation of TRB-N0224, a Proprietary Chemically-Modified Curumin, for the Treat

    SBC: TRAVERSE BIOSCIENCES, INC.            Topic: NIA

    DESCRIPTION (provided by applicant): Traverse Biosciences Inc. is a pre-clinical stage drug development company working to commercialize new chemical entities which act to resolve inflammatory conditions through pleiotropic host-modulation of pathologically unrestrained matrix metalloproteinases (MMPs) and pro-inflammatory cytokines. The company's lead drug candidate, TRB-N0224, is a proprie ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Developing a Nrf2 activator for the treatment of scleroderma

    SBC: CUREVEDA, LLC            Topic: NIAMS

    DESCRIPTION (provided by applicant): Scleroderma is a devastating autoimmune disease with a chronic course, involving the overproduction of collagen leading to fibrosis of the skin and connective tissues. The disease has a range of symptoms including pain,stiffness and swelling of the joints, shortness of breath and gastrointestinal complications. More than 50% of patients with the aggressive form ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Clinical Translation of Augmented Reality Visualization for Laparoscopic Surgery

    SBC: IGI TECHNOLOGIES, INC            Topic: NCI

    DESCRIPTION (provided by applicant): The overall objective of the proposed research is to fully develop and conduct clinical translation of a novel technology that provides minimally invasive surgeons an ability to visualize exposed organ surfaces as wellas structures hidden by them, together with a true appreciation of depth. A long-standing need in minimally invasive laparoscopic surgery has bee ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. A daily client check-in system for outpatient substance abuse treatment

    SBC: COG ANALYTICS, LLC            Topic: NIDA

    Abstract Alcohol and illicit drug use remain highly prevalent in the US, and epidemiological surveillance surveys estimate that over 20.6 million individuals (~ 8% of the US population) meet standard diagnostic thresholds for substance use disorders (SAMHSA, 2011). Outpatient substance abuse treatment is the predominate method of treatment in the US for SUDs, typically involving intermittent cont ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Drug Delivery Method for Sudden Sensorineural Hearing Loss

    SBC: WEINBERG MEDICAL PHYSICS, INC.            Topic: NIDCD

    DESCRIPTION (provided by applicant): The ultimate goal of the proposed project is to evaluate and commercialize a combination of proprietary magnet assemblies and magnetic nanoparticles (initially developed by our University STTR partner), that has been shown in preliminary animal studies to improve delivery of medications to the inner ear. Initial animal studies using the system (which uses magne ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government